Analysis updated on Oct. 15, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
On Oct. 15, 2026, GMAB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4016 stocks scored that day.
Genmab A/S is a large-cap company with a market capitalization of $23.73B. It ranks number 23 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/E Ratio of 1.48x is the lowest of the 25 peers that report one.
For GMAB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 8.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.3%, sell < +2.0%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GMAB included.
Follow GMAB free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in DKK and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
| Metric | GMAB | Rank |
|---|---|---|
| Market Cap | $23.73B | 23/60 |
| P/E Ratio | 1.48x | 25/25 |
| EPS | $24.89 | – |
| Revenue/Share | $8.43 | – |
| FCF/Share | $2.84 | – |
| Metric | GMAB | Rank |
|---|---|---|
| ROIC | 92.3% | 2/42 |
| Gross Margin | 95.4% | 4/32 |
| Operating Margin | 29.6% | 8/36 |
| EBT Margin | 41.0% | 8/43 |
| Tax Rate | 18.9% | – |
| Metric | GMAB | Rank |
|---|---|---|
| Current Ratio | 2.02x | 38/54 |
| Quick Ratio | 2.01x | 18/40 |
| D/E Ratio | 1.20x | 22/44 |
| Financial Leverage | 2.20x | 20/43 |
| Working Capital | $229M | 46/54 |
| Metric | GMAB | Rank |
|---|---|---|
| Operating Cash Flow | $1.87B | 16/53 |
| Free Cash Flow | $1.83B | 13/45 |
| Capital Spending | -$46M | 24/45 |
| OCF Growth YoY | -25.3% | 24/30 |
| FCF Growth YoY | 0.0% | 16/27 |
| FCF/Sales | 33.7% | 6/39 |
| CapEx/Sales | 0.8% | 30/39 |
| Metric | GMAB | Rank |
|---|---|---|
| Asset Turnover | 2.77x | 1/39 |
| Receivables Turnover | 32.1x | 3/37 |
| Inventory Turnover | 91.9x | 1/31 |
| Fixed Assets Turnover | 233.4x | 5/41 |
| Days Sales Outstanding | 11 days | 35/37 |
| Days Inventory | 4 days | 31/31 |
| Metric | GMAB | Rank |
|---|---|---|
| Total Revenue | $5.43B | 15/43 |
| Operating Income | $1.61B | 7/45 |
| R&D Expense | $2.51B | 11/52 |
| SG&A Expense | $947M | 21/38 |
| Cost of Goods Sold | $251M | 20/31 |
| Metric | GMAB | Rank |
|---|---|---|
| Shares Outstanding | 643M | – |
| EPS Growth | -17.6% | 7/12 |
| Total Current Assets | $454M | 22.4% of assets |
| Cash & Short-term Investments | $270M | 13.3% of assets |
| Accounts Receivable | $175M | 8.6% of assets |
| Inventory | $3M | 0.1% of assets |
| Total Liabilities | $1.10B | 54.6% of assets |
Companies classified under the same SEC industry code as Genmab A/S (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| GMAB Genmab A/S | ▶ | $23.73B |
| LLY Eli Lilly & Co | ▼ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ONC Beone Medicines Ltd. | ▶ | $519.53B |
| ABBV Abbvie Inc. | ▼ | $500.94B |
| MRK Merck & Co., Inc. | ▼ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| AZN Astrazeneca Plc | ▼ | $251.15B |
| ABT Abbott Laboratories | ▼ | $179.05B |
| PFE Pfizer Inc | ▶ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▼ | $121.09B |
| GSK Gsk Plc | ▼ | $96.58B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $80.14B |
| SNY Sanofi | ▼ | $48.50B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| RPRX Royalty Pharma Plc | ▶ | $33.92B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $30.04B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▶ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.28B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▲ | $14.97B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| ELAN Elanco Animal Health Inc | ▶ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.82B |
| CYTK Cytokinetics Inc | ▲ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.50B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B |
| ABVX Abivax S.A. | ▼ | $7.68B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.67B |
| ALKS Alkermes Plc. | ▲ | $6.56B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B |
| BLTE Belite Bio, Inc | ▲ | $6.01B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▲ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $4.03B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.02B |
| ABCL Abcellera Biologics Inc. | ▲ | $3.79B |
Barclays analyst James Gordon CFA maintained a Buy rating on Genmab A/S today and set a price target of DKK3,100.00. According to TipRanks, Gordon CFA is ranked #3970 out of 12448 analysts. In a ...
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...
Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen ...
On Oct. 15, 2026, GMAB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4016 stocks scored that day.
For GMAB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 8.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Genmab A/S forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
60 issuers in our coverage, GMAB included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.